Payment overview · 2025
General Payments
$449.33
12 reported records · 8 companies
Healthcare provider profile · identity verified
James L Lemley, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · THOMSON, GA · NPI 1952308926
Verified facts
What the public records show
CMS Open Payments records show James L Lemley, M.D. received $449.33 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.51 | 31.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $139.61 | 31.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.74 | 9.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.62 | 9.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.79 | 6.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.94 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.36 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.76 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $449.33 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.51 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $139.61 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 108 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 85 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 176 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
108 | 108 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
102 | 89 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
176 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
258 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 654 | 177 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 641 | 183 |
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 118 |
| Losartan Potassium | Losartan Potassium | 386 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 359 | 86 |
| Lisinopril | Lisinopril | 333 | 102 |
| Gabapentin | Gabapentin | 323 | 85 |
| Allopurinol | Allopurinol | 294 | 80 |
| Metformin Hcl | Metformin Hcl | 278 | 81 |
| Omeprazole | Omeprazole | 263 | 80 |
| Eliquis | Apixaban | 258 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 233 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 61 |
| Montelukast Sodium | Montelukast Sodium | 191 | 61 |
| Meloxicam | Meloxicam | 187 | 49 |
| Sertraline Hcl | Sertraline Hcl | 187 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 53 |
| Ozempic | Semaglutide | 176 | 25 |
| Carvedilol | Carvedilol | 169 | 48 |
| Metformin Hcl Er | Metformin Hcl | 153 | 47 |
| Tramadol Hcl | Tramadol Hcl | 147 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 29 |
| Furosemide | Furosemide | 139 | 46 |
| Potassium Chloride | Potassium Chloride | 139 | 40 |
| Simvastatin | Simvastatin | 139 | 36 |
| Clonazepam | Clonazepam | 138 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 30 |
| Jardiance | Empagliflozin | 136 | 25 |
| Finasteride | Finasteride | 128 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 34 |
| Trazodone Hcl | Trazodone Hcl | 123 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 111 | 69 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 32 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 108 | 108 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 32 |
| Famotidine | Famotidine | 105 | 36 |
| Glimepiride | Glimepiride | 105 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 29 |
| Azithromycin | Azithromycin | 104 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 102 | 89 |
| Celecoxib | Celecoxib | 99 | 25 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 98 | 25 |
| Lorazepam | Lorazepam | 98 | 16 |
| Alprazolam | Alprazolam | 96 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 93 | 27 |
| Pregabalin | Pregabalin | 90 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 86 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 33 |
| Farxiga | Dapagliflozin Propanediol | 85 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 27 |
| Bumetanide | Bumetanide | 81 | 28 |
| Doxepin Hcl | Doxepin Hcl | 80 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 22 |
| Amoxicillin | Amoxicillin | 78 | 53 |
| Donepezil Hcl | Donepezil Hcl | 75 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 13 |
| Ezetimibe | Ezetimibe | 65 | 20 |
| Methylprednisolone | Methylprednisolone | 65 | 52 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 47 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 19 |
| Mupirocin | Mupirocin | 63 | 42 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 60 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 17 |
| Memantine Hcl | Memantine Hcl | 56 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 13 |
| Atenolol | Atenolol | 54 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 43 |
| Meclizine Hcl | Meclizine Hcl | 52 | 25 |
| Nystatin | Nystatin | 52 | 17 |
| Buspirone Hcl | Buspirone Hcl | 51 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 12 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 16 |
| Terazosin Hcl | Terazosin Hcl | 47 | 11 |
| Sucralfate | Sucralfate | 46 | 20 |
| Fluconazole | Fluconazole | 45 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 44 | 44 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 15 |
| Fenofibrate | Fenofibrate | 42 | 12 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Lovastatin | Lovastatin | 39 | 11 |
| Alendronate Sodium | Alendronate Sodium | 38 | 12 |
| Chlorthalidone | Chlorthalidone | 38 | 12 |
| Baclofen | Baclofen | 37 | 13 |
| Spironolactone | Spironolactone | 37 | 13 |
| Cephalexin | Cephalexin | 36 | 28 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Prednisone | Prednisone | 35 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Estradiol | Estradiol | 31 | 11 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 22 |
| Primidone | Primidone | 31 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 26 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Glipizide | Glipizide | 25 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 13 |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Cholestyramine Light | Cholestyramine | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Flurbiprofen | Flurbiprofen | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $449.33 · 12 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, FARXIGA, Kerendia, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error